Tower Research Capital LLC (TRC)
Position in CTNM — Contineum Therapeutics, Inc.
CIK 1533421
NEW YORK, NY
Position in CTNM
as of Jun 30, 2026
· filed Aug 11, 2026
Position Value
$35,467
+$25,921 QoQ
Shares Held
2,164
+196.0% QoQ
Ownership
0.006%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#88
of 102 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in CTNM Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Tower Research Capital LLC (TRC) holds $49,479,230 across 466 Biotechnology names. CTNM ranks #170 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ARGX |
Argenx SE
|
4,547 | $4,218,570 | |
| 2 | BBIO |
BridgeBio Pharma, Inc.
|
38,206 | $2,845,582 | |
| 3 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
34,537 | $2,815,110 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
4,292 | $2,131,964 | |
| 5 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
3,927 | $2,108,602 | |
| 6 | AXSM |
Axsome Therapeutics, Inc.
|
6,437 | $1,575,584 | |
| 7 | INSM |
INSMED Inc
|
10,927 | $1,165,036 | |
| 8 | ROIV |
Roivant Sciences Ltd.
|
32,746 | $1,158,880 |
All Filings in CTNM
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $35,467 | 2,164 | Shares | Defined | 2026-08-11 | |
| 2026-03-31 | $9,546 | 731 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $1,417 | 124 | Shares | Defined | 2026-02-17 | |
| 2025-09-30 | $19,681 | 1,675 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $29,596 | 7,455 | Shares | Defined | 2025-08-15 | |
| 2025-03-31 | $9,478 | 1,358 | Shares | Defined | 2025-05-15 | |
| 2024-12-31 | $13,814 | 943 | Shares | Other | 2025-02-13 | |
| 2024-09-30 | $9,187 | 480 | Shares | Defined | 2024-11-14 | |
| 2024-06-30 | $1,655 | 94 | Shares | Other | 2024-08-13 | |
| No filing history on record for this holder in this stock. | ||||||